European Pharmaceutical Review

SEPTEMBER 22, 2023

According to a report by Research Nester, the global aseptic packaging market is projected to reach a revenue of $35 billion by 2033 and is estimated to reach a compound annual growth rate (CAGR) of 10 percent between 2023 and 2033. According to the report, European production has grown by approximately 5.4

Packaging 105

Packaging Vaccines Compounding 105

European Pharmaceutical Review

MARCH 11, 2024

In a review on fungal-contaminated compounded pharmaceuticals and medical devices, researchers have described how the contamination of these products can be due to breaches in sterile compounding procedures. Ahmed et al.

Sterile Compounds 98

Sterile Compounds Compounding Packaging Pharmaceutical Companies 98

European Pharmaceutical Review

MARCH 27, 2023

A report has predicted the rapid microbiology testing market size is estimated to grow at a compound annual growth rate (CAGR) of 9.31 2023 market share by region – global rapid microbiology testing market North America was projected to hold a 41 percent share of the market in 2023. percent between 2022 and 2027.

Compounding 115

Compounding Vaccines 115

European Pharmaceutical Review

NOVEMBER 28, 2023

Having been valued at $112 billion in 2022, the worldwide cold storage market is projected to witness a 12 percent compound annual growth rate (CAGR) between 2023 and 2032, according to a report by Towards Healthcare. Therefore, by the end of 2032, the market will value an estimated $383.05 billion, the research projected.

Compounding 98

Compounding Vaccines 98

pharmaphorum

AUGUST 25, 2022

Novartis started a review of the business in October 2021, after Sandoz had been suffering from pressure on sales and operating profits for several years due mainly to pricing pressures, which were then compounded by the pandemic. Since then, the unit has seen something of a financial recovery, with first half 2022 sales up 6% to $4.68

Compounding 105

Compounding Vaccines 105

European Pharmaceutical Review

MARCH 4, 2024

These biopharmaceuticals encompass a range of products including vaccines, recombinant therapeutic proteins, tissues, cells and gene therapies – all sourced from living organisms. Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5

FDA 98

FDA Vaccines Immunization Compounding 98

Hospital Pharmacy Europe

JUNE 27, 2024

Amidst the spotlight on vaccine development, therapeutic interventions remained a critical, yet often overlooked, aspect of pandemic preparedness. Therapeutics and pandemic management In its 2023 technical report on the Covid-19 pandemic in the UK , the Department of Health and Social Care described critical lessons learned.

Vaccines 52

Vaccines Compounding Immunization Hospitals 52

Hospital Pharmacy Europe

JUNE 27, 2024

Amidst the spotlight on vaccine development, therapeutic interventions remained a critical, yet often overlooked, aspect of pandemic preparedness. Therapeutics and pandemic management In its 2023 technical report on the Covid-19 pandemic in the UK , the Department of Health and Social Care described critical lessons learned.

Vaccines 52

Vaccines Compounding Immunization Hospitals 52

Hospital Pharmacy Europe

DECEMBER 5, 2024

mRNA vaccines: from Covid-19 and beyond The rapid success of messenger ribonucleic acid (mRNA) vaccines during the Covid-19 pandemic set the stage for broader applications, and in 2024, mRNA technology expanded significantly. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat Commun 2024;15:1553.

Vaccines 59

Vaccines Patient Care Compounding Pharmaceutical Companies 59

DiversifyRx

OCTOBER 5, 2022

Many people are curious to know if their antibody levels are high or low and how they change after a vaccine booster or a sickness. These should be an upsell for every person getting a vaccine in your pharmacy. I am already looking forward to Orlando for NCPA’s 2023 Annual Convention. Weight loss meds? No comments to show.

Independent Pharmacies 98

Independent Pharmacies Vaccines Compounding Immunization 98

pharmaphorum

AUGUST 31, 2022

The sheer number of treatment candidates moving through the pipeline has seen a recent report by Polaris Market Research predicts that the market will grow at a compound annual growth rate of 17.0% According to Eikonoklastes, ET-101 is expected to enter phase 1/2a studies in 2023. from 2021 to 2029. FDA backing. A broadening pipeline.

FDA 98

FDA Compounding Vaccines 98

The Checkup by Singlecare

SEPTEMBER 27, 2023

Nitrofurantoin can interact with certain antacids, gout medications, anesthetics, and travel vaccines. This includes some antacids, gout medications, anesthetics, and travel vaccines, as well as methotrexate and fluconazole. This includes the oral typhoid and cholera vaccines. coli, which is a bacteria that commonly causes UTIs.

Vaccines 52

Vaccines Mayo Clinic Compounding Communication 52

ISPE

MARCH 8, 2023

5 , 8 Compounding pharmacies were commonly mentioned as sources of microbial cross-contamination, especially in the US. 9 , 15 This has led to compounding pharmacies completing high-volume activities such as mass repackaging, thereby increasing the risk of cross-contamination. million vials, 26 had to be recalled and destroyed.

Compounding 52

Compounding Compounding Pharmacies Packaging FDA 52

The FDA Law Blog

DECEMBER 3, 2023

Below, we provide a high-level summary of the Final Guidance, focusing on the legal and regulatory updates from the May 2023 draft guidance. covered insulin product or vaccine). A “specified drug” means, for 2021, an applicable drug that is produced, prepared, propagated, compounded, converted, or processed by a specified manufacturer.

Labelling 105

Labelling Compounding Payment Processing Vaccines 105

Roots Analysis

JANUARY 27, 2025

It is important to note that, for the purpose of subcutaneous biologics market analysis, the biologics were segregated into antibodies , nucleotides, proteins and vaccines. The below figure presents the distribution of subcutaneous biologics based on initial approval year and type of biologic.

Hospitals 40

Hospitals Packaging Compounding Immunization 40

ISPE

OCTOBER 26, 2022

It seems like yesterday, and now the 2022 ISPE Annual Meeting & Expo in Orlando, Florida, has come and gone, and Mike Rutherford is the 2022–2023 Chair. This interaction was used to further improve the ISPE Charter, and the proposed changes will be implemented into the 2023 version. One ISPE and Strategic Plan Refresh.

Packaging 52

Packaging Compounding Communication Vaccines 52

The Checkup by Singlecare

OCTOBER 6, 2023

However, its use can result in serious adverse effects that other medications with similar side effect profiles can compound. Key takeaways: Methylprednisolone is an effective therapeutic agent to control immune responses and inflammation.

Vaccines 52

Vaccines Mayo Clinic FDA Immunization 52

European Pharmaceutical Review

JANUARY 29, 2024

N-Nitrosamines By far the biggest issue bedevilling industry during 2023 was the continuing N-nitrosamine contamination saga, which was covered in the third issue of EPR 2023. During August 2023 the FDA also updated its guidance for NDSRIs 7 and it was closely aligned (but not identical) to EMA’s evolving guidance.

FDA 111

FDA Vaccines Compounding 111

pharmaphorum

JANUARY 9, 2023

This Nine for 2023 three-part series will argue that, this year, the future-facing Janus prediction of unprecedented and transformative change is true. However, the pandemic is only one of the often deep-rooted forces that will come together in 2023 to exert transformative pressure on healthcare.

Vaccines 98

Vaccines Pharmaceutical Companies Pharmaceutical Companies Documentation 98

The Checkup by Singlecare

DECEMBER 19, 2022

Vaccines not covered by Medicare Part B. The late enrollment penalty will compound monthly for each month without coverage and never goes away. Starting in 2023, there is a cap being set on insulin. Each drug tier will outline the cost-sharing for prescription medications. . What’s not covered.

Mail-Order Pharmacies 52

Mail-Order Pharmacies Insurance Compounding Vaccines 52

Pharmaceutical Technology

DECEMBER 16, 2022

Novel therapeutics and vaccines for malaria. MMV and Novartis have worked on the upcoming Phase III study’s plans over the course of this year and plan to start the study in 2023, says MMV CEO David Reddy. According to the WHO’s October 2021 recommendation , the vaccine resulted in a 30% reduction of deadly severe malaria.

Vaccines 105

Vaccines Compounding FDA 105

Pharmaceutical Technology

MAY 18, 2023

Due to take place on 19–21 May 2023 in Hiroshima, the 49 th summit will discuss obstacles to human rights worldwide, including universal health coverage (UHC), a G7 priority. Neglected tropical diseases are a major global health concern, affecting over 1.7 billion people, many of whom live in the poorest and most vulnerable communities.

Vaccines 52

Vaccines Compounding FDA 52

Hospital Pharmacy Europe

NOVEMBER 23, 2023

With survey responses from 35 countries between November 2022 and March 2023, Keele University was commissioned to analyse the results and measure pharmacists’ progress against the statements and identify key barriers and drivers of success.

Hospitals 52

Hospitals Compounding Patient Care Vaccines 52

ISPE

SEPTEMBER 11, 2023

Considerations for a Decentralized Manufacturing Paradigm Trudy Patterson Mon, 09/11/2023 - 06:47 Features September / October 2023 Considerations for a Decentralized Manufacturing Paradigm Marquerita Algorri, PhD Ting Wang, PhD Jocelyn X. 7 June 2023. McQueen Nina S. 5 , 13 , 27 , 32 1 US Food and Drug Administration.

Health and Personal Care Stores 52

Health and Personal Care Stores Vaccines Packaging Documentation 52

PharmaShots

APRIL 3, 2023

Shots: The first quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Date - Jan 04, 2023 Product – N/A The acquisition is completed from a shareholder group led by Nordic Capital, in an all-cash transaction valued at $2.8B per ADS up front & CVR of ~$2.50

FDA 40

FDA Compounding Vaccines Hospitals 40

STAT

JANUARY 22, 2025

A source close to the case confirmed that the appeals court “declared inadmissible” a set of complaints brought in 2023 by Belgian former lobbyist Frederic Baldan, as he could not prove suffering “personal harm.”

FDA 112

FDA Compounding Vaccines 112

Pharmaceutical Technology

MARCH 22, 2023

During the Covid-19 pandemic, large-scale vaccine production placed unprecedented demand on the parenteral packaging industry. While production volumes have now fallen, future vaccine demand is hard to predict, as booster shots could be needed at any point to control emerging variants.

Packaging 52

Packaging Compounding Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

MAY 22, 2023

The possibility of additional funding comes at a time replete with investor uncertainty as a result of ongoing financial instability in the market, which has been compounded by the collapse of Silicon Valley Bank (SVB) and Credit Suisse.

Vaccines 111

Vaccines Compounding Communication 111